Reuel Uy
Internal Medicine · Vancouver, WANPI 1235546516
Payments from drug & device makers
Across 133 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$953
- Novo Nordisk$319
- Lilly USA, LLC$237
- Boehringer Ingelheim$153
- Esperion Therapeutics, Inc.$140
- Takeda Pharmaceuticals U.S.A., Inc.$116
- plus $645 from 13 others
What the payments were for
- Food & beverage$2,564100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $953 |
| Novo Nordisk | 18 | $319 |
| Lilly USA, LLC | 10 | $237 |
| Boehringer Ingelheim | 8 | $153 |
| Esperion Therapeutics, Inc. | 6 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $116 |
| Bayer | 1 | $104 |
| AstraZeneca | 4 | $101 |
| Sunovion Pharmaceuticals Inc. | 4 | $83 |
| GSK | 6 | $78 |
| Merck | 3 | $55 |
| Johnson & Johnson | 4 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Astellas Pharma US Inc | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Dexcom, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,564 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $59,236 |
| PradaxaDabigatran Etexilate Mesylate | 110 | $26,712 |
| Spiriva RespimatTiotropium Bromide | 31 | $24,247 |
| EliquisApixaban | 29 | $24,072 |
| JardianceEmpagliflozin | 38 | $14,420 |
| Wixela InhubFluticasone Propion/Salmeterol | 30 | $6,520 |
| Insulin Glargine-Yfgn | 20 | $4,798 |
| Atorvastatin Calcium | 367 | $4,027 |
| AlvescoCiclesonide | 32 | $3,830 |
| Humulin N KwikpenInsulin Nph Human Isophane | 14 | $3,640 |
| Potassium Chloride | 86 | $3,596 |
| Losartan Potassium | 284 | $3,258 |
| Levothyroxine Sodium | 193 | $3,192 |
| Humulin NInsulin Nph Human Isophane | 20 | $3,109 |
| Gabapentin | 125 | $2,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimPradaxa, Spiriva Respimat, Jardiance | $153 | $65,379179 claims |
| Novo NordiskOzempic | $319 | $59,23680 claims |
| PfizerEliquis | $11 | $24,07229 claims |
| Lilly USA, LLCHumulin N | $237 | $3,10920 claims |
| GSKShingrix | $78 | $2,20011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Vancouver
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
- Shelly KhuranaLynnwood$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.